Clinical Outcomes in Small Neuroendocrine Tumours Treated with Intestinal Surgery in Tertiary Centre Abstract #1746

Introduction: Patients with Small Bowel Neuroendocrine Tumours (SBNET) may require small bowel surgery either as an emergency or electively.Robust data from Tertiary Referral Centres (TRC) are lacking.
Aim(s): To assess the short-term outcome, disease progression and overall survival of patients with SBNETs who underwent intestinal surgery in a TRC.
Materials and methods: 37 patients with SBNET who underwent intestinal surgery in our unit were retrospectively analyzed.Data included gastrointestinal (GI) symptoms pre-surgery, hepatic/Mesenteric Metastasis (MM) and desmoplasia.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Georgios Demetriou

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1744 Predictors of Survival in Patients with Small Intestinal Neuroendocrine Tumours (SINETs) Associated with Mesenteric Desmoplasia
Introduction: SINETs represent 30-50% of small bowel neoplasms with a rising incidence and can be associated with mesenteric fibrosis (MF)
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Faidon M Laskaratos
Keywords: SINETs
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team